Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
Disitamab vedotin-toripalimab led to a significantly greater improvement in outcomes than chemotherapy among patients with untreated HER2-expressing locally advanced or metastatic urothelial cancer. (Funded by RemeGen and others; RC48-C016 ClinicalTrials.gov number, NCT05302284; ChinaDrugTrials.org.cn number, CTR20220348.).
Authors
- Cuijian Zhang
- Haitao Niu (ORCID: https://orcid.org/0000-0002-8442-7444)
- Guoxian Ma
- Kai Yao (ORCID: https://orcid.org/0000-0002-2589-3058)
- Xiaolong Qi
- Baiye Jin (ORCID: https://orcid.org/0000-0002-6667-0424)
- Jianmin Fang (ORCID: https://orcid.org/0000-0002-4332-4967)
- Xinan Sheng (ORCID: https://orcid.org/0000-0001-9359-0975)
- Gongqian Zeng
- Yanxia Shi (ORCID: https://orcid.org/0000-0002-5414-8049)
- Xue‐Yi Xue (ORCID: https://orcid.org/0000-0002-6461-7435)
- Jian Gu (ORCID: https://orcid.org/0000-0003-3499-0973)
- Zhisong He
- Jiasheng Bian
- Zhixian Yu (ORCID: https://orcid.org/0000-0002-1226-7891)
- Beisong Liu
- Peng Zhao
- Xin Gou (ORCID: https://orcid.org/0000-0001-5707-0753)
- Qin Yang (ORCID: https://orcid.org/0000-0003-1091-2954)
- Tiejun Yang (ORCID: https://orcid.org/0000-0002-9635-1707)
- Lu Zhang (ORCID: https://orcid.org/0000-0001-7141-6730)
- Jun Guo (ORCID: https://orcid.org/0000-0002-2089-7105)
- Hong Liao
- Aiping Zhou (ORCID: https://orcid.org/0000-0003-1632-837X)
- Jian Huang (ORCID: https://orcid.org/0000-0002-6676-5159)
- Bin Hu (ORCID: https://orcid.org/0000-0002-8509-6069)
- Jun Li (ORCID: https://orcid.org/0000-0003-0891-4328)
- Xianling Liu (ORCID: https://orcid.org/0000-0002-4237-1227)
- Qingyun Zhang (ORCID: https://orcid.org/0000-0002-7269-7009)
- Shusuan Jiang
- Ziling Liu
Institutions
- Qingdao University (CN)
- Tongji University (CN)
- Fujian Medical University (CN)
- Central South University (CN)
- Guiyang Medical University (CN)
- Sun Yat-sen University (CN)
- Chongqing University (CN)
- Guangxi Medical University (CN)
- Yantai University (CN)
- Jilin University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- National Cancer Center (US)
- Sun Yat-sen Memorial Hospital (CN)
- Shandong Tumor Hospital (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Hunan Cancer Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Sichuan Cancer Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- First Hospital of Jilin University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Peking University First Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Ministry of Education (ET)
- Second Xiangya Hospital of Central South University (CN)
- Chongqing Cancer Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Shandong First Medical University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-19
- DOI
- https://doi.org/10.1056/nejmoa2511648
- Citations
- 27
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 54.17